MENU
CTMX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
CytomX Therapeutics (CTMX) Ownership - Who owns CytomX Therapeutics?
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
151 Oyster Point Boulevard
Phone
+1 650 515-3185
Employees
122
Web
https://www.cytomx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
356.05M
P/E Ratio
4.71
Total Cash
79.89M
Projected Growth
N/A
Total Debt
8.15M
Revenue
147.56M
Risk (Beta)
2.83
Dividend Yield
N/A
Total Cash/Share
0.51
Total Debt/Equity
N/A
Revenue/Share
1.72 USD as % of share price
Fundamentals
CTMX
Capitalization
356M
P/E Ratio
4.71
Risk (Beta)
2.83
Dividend Yield
N/A
Total Cash
79.9M
Total Cash/Share
0.51
Total Debt
8.15M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.72%
Revenue
148M
ROE
N/A
Book Value
25M
P/B Ratio
14.14
Cash Flow
N/A
Earnings
0.48
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
1K
Current Ratio
1.73
Current Revenue Per Employee
420801.66
Dividends Per Share - Security
N/A
EBITDA
37.6M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
29.38
Shares Held By Institutions
43.9M
Shares Outstanding - Current
158M
Total Liabilities
73.4M
Total Volume MTD
N/A
Value
-1
Gain YTD
118.447
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
151 Oyster Point Boulevard
Phone
+1 650 515-3185
Employees
122
Web
https://www.cytomx.com